Alison Schram
@AliSchram
Followers
871
Following
613
Media
9
Statuses
81
Medical Oncologist, Early Drug Development and Gynecologic Malignancies, Memorial Sloan Kettering Cancer Center.
New York, USA
Joined December 2015
Now available on pubmed! Results of the zenocutuzumab (Bizengri) basket trial in NRG1 fusion + solid tumors. This trial led to recent FDA approval in lung and pancreatic cancer. RNA seq is critical to identify these fusions. 🧬@NEJM
pubmed.ncbi.nlm.nih.gov
Zenocutuzumab showed efficacy in patients with advanced NRG1 fusion-positive cancer, notably NSCLC and pancreatic cancer, with mainly low-grade adverse events. (Funded by Merus; eNRGy ClinicalTrial...
0
1
8
RT @IASLC: #ICYMI, the FDA recently approved zenocutuzumab for NSCLC with an NRG1 fusion! Catch this all-new episode of #LungCancerConsider….
0
7
0
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
416
685
3K
I am commonly asked what the benchmarks are for a target-drug pair to have tumor-agnostic potential. See the new ETAC-S! @Annals_Oncology @myESMO @VivekSubbiah @JulianaRBeal @curijoey @Dr_R_Kurzrock @SewantiLimaye @StefanMichiels @quimmateo @niamhjcoleman @FAndreMD @ElenaGarralda.
ESMO announces the publication of the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S), a new framework to assess the tumour-agnostic potential of #CancerTherapies with the aim to optimise the drug development process @Annals_Oncology. 🔗
1
9
26
I second this. Pat you are a powerhouse, role model, mentor, brilliant trialist and compassionate doctor. AACR is in the best hands. Congrats! @AACRPres.
One of the kindest, smartest and generous humans I know! Congrats Pat!!!.
0
0
5
Fun session thanks to @VivekSubbiah, Christophe Le Tourneau, and Jordi Rodon complete with a sonnet about tumor agnostic drug development by ChatGPT/Vivek! 🎯🧬💊😂.
⭐️@AliSchram @MSKCancerCenter just after a phenomenal presentation of the tumor agnostic data from the lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor in FGFR2-altered tumors. Dr. Schram nailed it at the Q &A session. 👉🏼So amazing to watch the @Relay_Tx drug go
0
2
26
RT @VivekSubbiah: ⭐️Mark your calendars if you are attending the triple meeting 👉 Super thrilled to be discussing about the "Future of Tiss….
0
13
0
Well deserved! @TinaJost4 I hope you continue this great work on the mechanism of radiosensitization and most effective use of DDR therapies.
Thanks to @AliSchram and #esmotat23 for the best poster price on kinase-targeting agents and cell signalling modulators. #dnarepair #kinaseinhibitors #targetedtherapy
0
0
3
RT @NeilVasan: We are pleased to announce our manuscript on pan-cancer multi-PIK3CA mutations, published this week in @CCR_AACR. https://t….
0
23
0
RT @VivekSubbiah: 🎯On behalf of all co-investigators presenting👉Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma using a nove….
0
23
0
In case you missed it, updated results from the eNRGy study presented at #ASCO22! Zeno ORR of 34% (27/79) across tumor types & 42% (8/19) in PDAC. Median DOR of 9.1 mo and extremely well tolerated. Zeno has the potential to become new SOC for this unmet clinical need.
2
41
127
Grateful to be involved in this exciting study demonstrating efficacy targeting the elusive p53 (Y220C). Cool biology and helping patients!.
Looking forward to this #ASCO22 presentation by @cathy_ileana_md on a first-in-class mutant p53 structural corrector
0
1
8
RT @MSKCancerCenter: Despite having lost her voice, @HillaSolomon told us all about her group's research on possible #EndometrialCancer tre….
0
4
0
Thrilled to share MSKs preclinical and initial clinical experience with Zeno which led to the ongoing eNRGy study. Treating these pts has been a highlight of my career. Grateful to have incredible lab collaborators and be at @sloan_kettering where anything is possible.
Now online in @CD_AACR: Zenocutuzumab, a #HER2 x #HER3 #bispecific antibody, is effective therapy for tumors driven by #NRG1 gene rearrangements - by @AliSchram @odintosov_I Romel Somwar and colleagues @sloan_kettering
6
4
63
Game changing for our patients. Congrats #VickyMakker @sloan_kettering and everyone involved!.
Endometria ca:The median OS ⬆️ with lenvatinib+ pembro than with chemo (pMMR: 17.4 vs. 12 mos; HR for death, 0.68; 95% CI, 0.56 to 0.84; P<0.001; overall: 18.3 vs. 11.4 mos; HR, 0.62; 95% CI, 0.51 to 0.75; P<0.001). @NEJM @sloan_kettering
0
0
16
RT @TeamEndo_MSK: 🔎Do you know the symptoms of #UterineCancer? . Dr. @AliSchram discusses common symptoms with @healthmagazine. This collab….
health.com
Signs of uterine cancer may include irregular vaginal bleeding, unusual vaginal discharge, pain, bloating, gastrointestinal issues, and unexpected weight loss.
0
6
0
Congrats to @CDebyaniPhD @nikolausschultz @DSolit and everyone involved! OncoKB is a game changer for patients, clinicians, and trials. It’s impossible to fully appreciate the impact it has on patient care. I reference it multiple times a day👩🏽💻Thanks for this incredible resource!.
🚨 Breaking News: @US_FDA grants partial recognition status to MSK's #precisiononcology knowledge database #OncoKB. This database is the first database of somatic variants in cancer to be recognized by the FDA. . @CDebyaniPhD @DSolit @nikolausschultz.
1
0
24
Congrats to my deserving husband @DanielGorovets on becoming associate program director of @MSK_RadOnc !.
📢Proud to formally announce Dr @LiorBraunstein as the new #radonc @sloan_kettering Program Director with Dr @hajjcmskccorg1 and Dr @DanielGorovets as Associate PDs. 👏We appreciate all of the incredible work that Dr @abewu has put in as PD over the past seven years.
1
1
45